Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Benitec Biopharma (BNTC) over the last 6 years, with Q2 2025 value amounting to $2.5 million.

  • Benitec Biopharma's Cash from Financing Activities fell 9365.13% to $2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $70.5 million, marking a year-over-year increase of 361.02%. This contributed to the annual value of $70.5 million for FY2025, which is 361.02% up from last year.
  • Benitec Biopharma's Cash from Financing Activities amounted to $2.5 million in Q2 2025, which was down 9365.13% from $28.4 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Cash from Financing Activities peaked at $40.1 million during Q2 2024, and registered a low of $3000.0 during Q1 2021.
  • Over the past 5 years, Benitec Biopharma's median Cash from Financing Activities value was $16.9 million (recorded in 2022), while the average stood at $16.7 million.
  • Per our database at Business Quant, Benitec Biopharma's Cash from Financing Activities surged by 4572051.28% in 2024 and then crashed by 9365.13% in 2025.
  • Over the past 5 years, Benitec Biopharma's Cash from Financing Activities (Quarter) stood at $12.7 million in 2021, then increased by 26.42% to $16.0 million in 2022, then tumbled by 99.76% to $39000.0 in 2023, then soared by 45720.51% to $17.9 million in 2024, then tumbled by 85.76% to $2.5 million in 2025.
  • Its Cash from Financing Activities was $2.5 million in Q2 2025, compared to $28.4 million in Q1 2025 and $17.9 million in Q4 2024.